leisure time -WSS

leisure time

author：comprehensive 2025-08-31 02:02:21 - browse：93

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Florida health officials providing scant details on measles cases

WSS

Roche to buy Carmot Therapeutics, developer of obesity drugs

Stem cell biologist probes earliest stages of human development

Pregnant women don't need prenatal multivitamins, study concludes

Streamlined flu vaccines recommended by FDA advisory panel

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Medical records are filled with copy

Teach medical students about patients with intellectual disabilities

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

STAT letters to the editor on burnt

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Chemotherapy shortages won’t get better under Biden’s latest plan

Sports medicine is finally prioritizing gender equality

For AI in health care standards, federal regulators join with industry group

Medical records are filled with copy

Radiology is caught between AI's potential and concern for patients

Wikipedia

For AI in health care standards, federal regulators join with industry group

First over

FDA approves world's first CRISPR

The woman behind the Dana Farber

Readout Newsletter: BridgeBio, Akero, and human embryo models

Patients' immediate access to test results puts radiologists in a bind

focus

focus

explore

leisure time